Illumina, Inc. vs Zeta Global Holdings Corp — how do they compare? Illumina, Inc. trades at $278.17 (market cap $39.95B), while Zeta Global Holdings Corp trades at $33.09 (market cap $8.29B). The key difference: Illumina, Inc. is far larger — about 4.8× Zeta Global Holdings Corp's market cap, and Zeta Global Holdings Corp is more actively traded (7,156,795 versus 3,169,503). Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Zeta Global Holdings Corp for 19 Days on average.
| ILMN | ZETA | |
|---|---|---|
Market Cap | $39.95B | $8.29B |
Volume | 3,169,503 | 7,156,795 |
Sector | Health | Technology |
52-Week High | $293.69 | $33.74 |
52-Week Low | $91.00 | $14.55 |
Typical Hold Time | 83 Days | 19 Days |
Enterprise Value | $41.31B | $8.18B |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $264.40, down 1.25% on the day but remains near its 52-week high of $278.99, reflecting strong momentum with a 94.9% YTD gain. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Fundamentals show a significant turnaround, with net income reaching $850 million in 2025 after prior losses, supported by robust gross margins of 66.38%. Technical indicators are bullish overall, with key support at $257 and resistance at $268.
The outlook for ILMN is positive, driven by earnings momentum, inclusion in the S&P 500, and strategic AI initiatives in genomics. However, risks include high valuation multiples, such as a P/E of 49.36, and potential margin pressure from cost volatility. Analyst consensus is bullish with a 54% buy rating, though the consensus price target of $241 suggests limited near-term upside from current levels.
ZETA trades at $33.03, down 2.1% today but remains near recent highs with strong technical momentum. The company shows robust revenue growth with $1.3B in 2025 and projected $1.6B in 2026, though profitability remains challenged with negative net margins. Recent earnings beats and expanding customer base (197 superscale customers in Q2 2026) support the bullish analyst consensus.
ZETA presents a growth story with expanding AI platform adoption and international expansion, but faces execution risks amid negative cash flow and high valuation multiples. The stock's 75% buy rating from analysts suggests upside potential, though investors should monitor margin improvement and cash flow sustainability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →Zeta Global is a leading data-driven marketing technology company that provides an omnichannel AI Marketing Cloud. By leveraging a proprietary data cloud of over 2.4 billion deterministic identities, it enables enterprise brands to acquire, grow, and retain customers through predictive intelligence and automated, agentic workflows.
Read more on ZETA →